Insider Transactions in Q1 2021 at Intercept Pharmaceuticals, Inc. (ICPT)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 31
2021
|
Mark Pruzanski Director |
SELL
Payment of exercise price or tax liability
|
Direct |
3,658
-0.73%
|
$84,134
$23.08 P/Share
|
|
Mar 31
2021
|
Mark Pruzanski Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,136
+1.2%
|
$141,128
$23.08 P/Share
|
|
Mar 12
2021
|
Srinivas Akkaraju Director |
BUY
Open market or private purchase
|
Indirect |
147,000
+18.66%
|
$3,087,000
$21.29 P/Share
|
|
Mar 10
2021
|
Srinivas Akkaraju Director |
BUY
Open market or private purchase
|
Indirect |
90,000
+8.29%
|
$1,890,000
$21.19 P/Share
|
|
Feb 27
2021
|
Christian Weyer EVP, Research & Development |
SELL
Payment of exercise price or tax liability
|
Direct |
357
-1.29%
|
$7,497
$21.66 P/Share
|
|
Feb 26
2021
|
Mark Pruzanski Director |
SELL
Payment of exercise price or tax liability
|
Direct |
2,741
-0.55%
|
$57,561
$21.66 P/Share
|
|
Feb 26
2021
|
Mark Pruzanski Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,138
+1.21%
|
$128,898
$21.66 P/Share
|
|
Feb 23
2021
|
Jerome Benedict Durso CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
319
-0.39%
|
$8,932
$28.12 P/Share
|
|
Feb 15
2021
|
Linda M Richardson EVP & Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,531
+17.07%
|
-
|
|
Feb 12
2021
|
Gail Cawkwell SVP, Med Affairs, Safety & PV |
SELL
Payment of exercise price or tax liability
|
Direct |
319
-0.96%
|
$9,889
$31.32 P/Share
|
|
Feb 08
2021
|
David A Ford Chief Human Resources Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
148
-0.61%
|
$5,328
$36.04 P/Share
|
|
Feb 01
2021
|
Jared Freedberg General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
44,277
+50.0%
|
-
|
|
Jan 29
2021
|
Mark Pruzanski Director |
SELL
Payment of exercise price or tax liability
|
Direct |
2,741
-0.55%
|
$95,935
$35.24 P/Share
|
|
Jan 29
2021
|
Mark Pruzanski Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,138
+1.22%
|
$214,830
$35.24 P/Share
|
|
Jan 22
2021
|
Gail Cawkwell SVP, Med Affairs, Safety & PV |
BUY
Grant, award, or other acquisition
|
Direct |
12,600
+27.52%
|
-
|
|
Jan 22
2021
|
Jerome Benedict Durso CEO |
BUY
Grant, award, or other acquisition
|
Direct |
46,000
+35.73%
|
-
|
|
Jan 22
2021
|
Jason Campagna Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,600
+38.03%
|
-
|
|
Jan 22
2021
|
David A Ford Chief Human Resources Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,500
+32.32%
|
-
|
|
Jan 22
2021
|
Sandip Kapadia CFO and Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
17,200
+29.57%
|
-
|
|
Jan 22
2021
|
Christian Weyer EVP, Research & Development |
BUY
Grant, award, or other acquisition
|
Direct |
12,600
+31.23%
|
-
|
|
Jan 11
2021
|
Bryan Ball Chief Qual. Officer & SVP Ops. |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+50.0%
|
-
|
|
Jan 05
2021
|
Sandip Kapadia CFO and Treasurer |
SELL
Open market or private sale
|
Direct |
2,193
-8.45%
|
$52,632
$24.47 P/Share
|
|
Jan 01
2021
|
Jerome Benedict Durso CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
334
-0.9%
|
$8,016
$24.7 P/Share
|
|
Jan 01
2021
|
Jason Campagna Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
132
-1.64%
|
$3,168
$24.7 P/Share
|
|
Jan 01
2021
|
David A Ford Chief Human Resources Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
106
-0.84%
|
$2,544
$24.7 P/Share
|
|
Jan 01
2021
|
Sandip Kapadia CFO and Treasurer |
SELL
Payment of exercise price or tax liability
|
Direct |
342
-1.3%
|
$8,208
$24.7 P/Share
|
|
Jan 01
2021
|
Richard J Kim President US Comm & Strat Mktg |
SELL
Payment of exercise price or tax liability
|
Direct |
259
-1.29%
|
$6,216
$24.7 P/Share
|
|
Jan 01
2021
|
Mark Pruzanski Director |
SELL
Payment of exercise price or tax liability
|
Direct |
632
-0.13%
|
$15,168
$24.7 P/Share
|
|
Jan 01
2021
|
Christian Weyer EVP, Research & Development |
SELL
Payment of exercise price or tax liability
|
Direct |
54
-0.36%
|
$1,296
$24.7 P/Share
|